MXPA03011399A - Metodos para tratar la enfermedad de alzheimer. - Google Patents

Metodos para tratar la enfermedad de alzheimer.

Info

Publication number
MXPA03011399A
MXPA03011399A MXPA03011399A MXPA03011399A MXPA03011399A MX PA03011399 A MXPA03011399 A MX PA03011399A MX PA03011399 A MXPA03011399 A MX PA03011399A MX PA03011399 A MXPA03011399 A MX PA03011399A MX PA03011399 A MXPA03011399 A MX PA03011399A
Authority
MX
Mexico
Prior art keywords
disease
methods
treating alzheimer
inhibiting
beta
Prior art date
Application number
MXPA03011399A
Other languages
English (en)
Inventor
Alan Chrusciel Robert
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Publication of MXPA03011399A publication Critical patent/MXPA03011399A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)

Abstract

La presente invencion se refiere a metodos para tratar la enfermedad de Alzheimer y otras enfermedades y/o para inhibir la enzima beta-secretasa y/o para inhibir la deposicion de un peptido A beta en un mamifero, por medio del uso de compuestos de hidrazina de la formula (l) en donde las variables R1-R9 se definen en este texto.
MXPA03011399A 2001-06-08 2002-06-07 Metodos para tratar la enfermedad de alzheimer. MXPA03011399A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29694101P 2001-06-08 2001-06-08
PCT/US2002/018262 WO2002100410A1 (en) 2001-06-08 2002-06-07 Methods of treating alzheimer's disease

Publications (1)

Publication Number Publication Date
MXPA03011399A true MXPA03011399A (es) 2004-07-01

Family

ID=23144183

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03011399A MXPA03011399A (es) 2001-06-08 2002-06-07 Metodos para tratar la enfermedad de alzheimer.

Country Status (6)

Country Link
US (1) US20050130941A1 (es)
EP (1) EP1392315A1 (es)
JP (1) JP2005501015A (es)
CA (1) CA2449948A1 (es)
MX (1) MXPA03011399A (es)
WO (1) WO2002100410A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US20050239836A1 (en) * 2004-03-09 2005-10-27 Varghese John Substituted hydroxyethylamine aspartyl protease inhibitors
WO2005087752A2 (en) * 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamine aspartyl protease inhibitors
WO2006103038A1 (en) * 2005-03-30 2006-10-05 Boehringer Ingelheim International Gmbh Substituted 1,2-ethylendiamines, medicaments comprising said compound; their use and their method of manufacture
EP1871739A1 (en) 2005-04-08 2008-01-02 Comentis, Inc. Compounds which inhibit beta-secretase activity and methods of use thereof
ES2574831T3 (es) * 2006-07-21 2016-06-22 Gilead Sciences, Inc. Inhibidores de la proteasa antivirales
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
CN112724033A (zh) * 2020-12-16 2021-04-30 山东天安化工股份有限公司 一种避蚊胺的合成方法及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753652A (en) * 1991-07-03 1998-05-19 Novartis Corporation Antiretroviral hydrazine derivatives
SG113454A1 (en) * 1998-09-24 2005-08-29 Upjohn Co Alzheimer's disease secretase
JP2002539183A (ja) * 1999-03-16 2002-11-19 サイトビア インコーポレイテッド 置換２−アミノベンズアミドカスパーゼインヒビターおよびその使用
US6455589B1 (en) * 1999-10-28 2002-09-24 The Regents Of The University Of California Primary N-hydroxylamines

Also Published As

Publication number Publication date
US20050130941A1 (en) 2005-06-16
WO2002100410A1 (en) 2002-12-19
CA2449948A1 (en) 2002-12-19
EP1392315A1 (en) 2004-03-03
JP2005501015A (ja) 2005-01-13

Similar Documents

Publication Publication Date Title
UA84407C2 (en) Acetyl 2-hydroxy-1,3 diaminoalkanes
WO2003103653A8 (en) METHODS OF TREATING ALZHEIMER'S DISEASE WITH ALKANOIC ARYL ACID AMIDES
WO2002076440A3 (en) Methods of treating alzheimer's disease with piperidin derivates
WO2003030886A3 (en) Allylamides useful in the treatment of alzheimer's disease
MXPA04003245A (es) Hidroxipropilaminas.
TW200505418A (en) Phenacyl 2-hydroxy-3-diaminoalkanes
DE60332137D1 (en) Cyclohexyl-sulphone als gamma-sekretase-inhibitoren
GB0225474D0 (en) Therapeutic agents
GB0225475D0 (en) Therapeutic agents
GB0318447D0 (en) Therapeutic agents
MXPA04000328A (es) Derivados de alfa-hidroxiamida estatina para tratamiento de enfermedad de alzheimer.
RS50504A (en) N,n'-substituted-1,3-diamino-2- hydroxypropane derivatives
MXPA05011150A (es) 2-hidroxi-3-diaminoalcanos de benzamida.
WO2004022523A3 (en) 1, 3-diamino-2-hydroxypropane prodrug derivatives
BR9909844A (pt) Processo para sintetizar um composto, e, composto.
MY135477A (en) 2-(2,6-dichlorophenyl)-diarylimidazoles
WO2005095326A3 (en) 2-amino- and 2-thio-substituted 1,3-diaminopropanes
HK1046403A1 (en) Nematicidal trifluorobutenes.
MXPA04002785A (es) Aminas sustituidas para tratamiento de enfermedad de alzheimer.
TW200505828A (en) Substituted ureas and carbamates useful in the treatment of alzheimer's disease
MXPA04000338A (es) Diamindioles para tratamiento de enfermedad de alzheimer.
MX9708621A (es) AGONISTAS beta-ADRENERGICOS, COMPOSICIONES QUE LOS CONTIENEN Y USO DE LOS MISMOS.
MXPA03011466A (es) Macrociclos utiles en tratamiento de enfermedades de alzheimer.
AU2002356991A1 (en) Amino acid derivatives useful for the treatment of alzheimer's disease
AP2002002387A0 (en) Method of inhibiting amyloid aggregation and imaging amyloid deposits.